Search Results

Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q1 2024.

Bio-Path Holdings, Inc. announced its financial results for the first quarter ended March 31, 2024 and provided an update on recent corporate developments.

Bio-Path Holdings, Inc. announced an upcoming poster presentation at the 2024 European Hematology Association Congress, taking place June 13-16, 2024 in Madrid, Spain.

Bio-Path Holdings, Inc. announced an upcoming oral presentation at the American Society of Clinical Oncology Annual Meeting, taking place May 31 - June 4, 2024 in Chicago, IL.

Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced the receipt of newly issued patents in Mexico, Australia and Japan, and updated investors on the extent of its global intellectual property portfolio.

Bio-Path Holdings, Inc. announced that it will host a live conference call and audio webcast on Wednesday, May 15, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024 and to provide a business overview.

Bio-Path Holdings, Inc. announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 375,000 shares of its common stock at a purchase price per share of $3.225 in a registered direct offering priced at-the-market under Nasdaq rules.